leisure time -WSS

leisure time

author：focus 2025-09-30 22:27:16 - browse：71

A pharmacist hands a box of Wegovy — first opinion coverage from STAT — Bloomberg photo by George Frey

LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch had led it to limit doses last May.

The announcement that Novo was making more of its lower-dose starter product available as of this month came as the company reported its 2023 earnings, with sales up by 36% and operating profit up 44% at constant exchange rates, driven by enormous sales of Wegovy and Ozempic, the company’s sister drug for diabetes. The company also projected double-digit growth in sales and operating profit for 2024.

“I am pleased to state that we are now enabling more new U.S. patients to initiate treatment by more than doubling the amount of lower-dose strength Wegovy compared to previous months,” Novo CEO Lars Fruergaard Jørgensen said on a call with reporters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Drastic changes should bring profitability, startup health insurers say

WSS

Why failed clinical trials don’t always spell doom for a new drug

The best solution to the drug shortages problem

South Korea throws huge K

A biotech analyst on neuroscience, placebo effect, not over

Friends ask where James Watson's attitudes about race came from

Researchers CRISPR chickens in bid to protect them from bird flu

focus

leisure time

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Affirmative action in medical school literally saved lives

What's changing in Medicare's open enrollment this year?

BioMarin wins approval for gene therapy to treat hemophilia A

European regulators consider appeal over Amylyx ALS drug

Medicare details structure of new drug price negotiation program

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

State Dept. review finds Biden bears some blame for Afghanistan failures

What the Wegovy shortage looks like for doctors — and for patients

leisure time

European regulators consider appeal over Amylyx ALS drug

Medicare to cover more brain scans related to Alzheimer’s drugs

Why failed clinical trials don’t always spell doom for a new drug

Massive project maps cells in human brain in unprecedented detail

European regulators consider appeal over Amylyx ALS drug

Readout LOUD podcast: Merger Mondays, Ozempic panic

leisure time

explore

focus

knowledge